Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome |
Hwang, Kyu Ri
(Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Choi, Young Min (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Kim, Jin Ju (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Chae, Soo Jin (Maria Fertility Hospital) Park, Kyung Eui (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Jeon, Hye Won (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Ku, Seung Yup (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Kim, Jung Gu (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) Moon, Shin Yong (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) |
1 | Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo- controlled trial. J Clin Endocrinol Metab 2002;87:569-74. DOI |
2 | Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9. DOI |
3 | Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-10. DOI |
4 | Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774-800. |
5 | Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54. DOI |
6 | Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46. |
7 | Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13. DOI |
8 | Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;196:402.e1-10. DOI |
9 | Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3835-40. DOI |
10 | Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007; 157:669-76. DOI |
11 | Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod 2010;25:1005-13. DOI |
12 | Koenen TB, Tack CJ, Kroese JM, Hermus AR, Sweep FC, van der Laak J, et al. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 2009; 94:4453-7. DOI |
13 | Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-8. DOI |
14 | Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and in sulin resistance to metformin and pioglitazone in obese, insulinresistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5. DOI |
15 | Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2009;94:469-76. DOI |
16 | Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002;87:4088-93. DOI |
17 | Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25. |
18 | Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006;30:13-7. DOI |
19 | Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003;18: 1618-25. DOI |
20 | Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-31. DOI |
21 | Hwang KR, Choi YM, Choi DS, Baek KH, Jeon HW, Bae KB, et al. Effect of metformin treatment and insulin resistance in patients with polycystic ovary syndrome. Korean J Obstet Gynecol 2004; 47:1949-53. |
22 | Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9. DOI |
23 | Hucking K, Watanabe RM, Stefanovski D, Bergman RN. OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself. Obesity (Silver Spring) 2008; 16:1938-45. DOI |
24 | Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97:18-22. DOI |
25 | Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008;93:792-800. DOI |
26 | Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999;14:2963-8. DOI |
27 | Koo YA, Shin SY, Yoon BK, Choi D. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Gynecol Endocrinol 2007; 23:461-7. DOI |
28 | Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527-37. DOI |